节点文献

子宫颈癌筛查史在子宫颈癌前病变风险分层中的作用

The role of cervical cancer screening history in assessing the risk of cervical precancerous lesions

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 张小松朱信信毕蕙赵清平傅云峰吴琼燕张丽娜张春梅黄宁

【Author】 ZHANG Xiaosong;ZHU Xinxin;BI Hui;ZHAO Qingping;FU Yunfeng;WU Qiongyan;ZHANG Li’na;ZHANG Chunmei;HUANG Ning;Department of Obstetrics and gynecology, Peking University First Hospital;Department of Cervical Disease, Sichuan Provincial Maternity and Child Health Care Hospital;Medical Centre for Cervical Diseases, Women’s Hospital, Zhejiang University School of Medicine;Medical Centre for Cervical Diseaset, Changzhou Maternal and Child Health Care Hospital;Medical Centre for Cervical Disease, Yanbian Maternal and Child Health-Care Hospital;Department of Gynecology,The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous;

【通讯作者】 毕蕙;

【机构】 北京大学第一医院妇产生殖医学中心四川省妇幼保健院宫颈疾病防治中心浙江大学医学院附属妇产科医院宫颈疾病诊治中心常州市妇幼保健院宫颈疾病诊治室中心延边妇幼保健院宫颈疾病诊疗保健中心广西壮族自治区妇幼保健院宫颈疾病防治中心

【摘要】 目的 评估子宫颈癌筛查史对于子宫颈癌前病变/子宫颈癌的风险,为子宫颈上皮内病变的精细化管理提供参考依据。方法 对2021年9—12月在北京大学第一医院等6家医疗机构2 832例进行阴道镜检查的非妊娠女性子宫颈癌筛查信息进行回顾性分析,主要包括既往子宫颈癌筛查史、本次筛查结果、阴道镜检查情况及活检情况和结果。结果 既往未参加过子宫颈癌筛查女性中,本次高危型人乳头瘤病毒(HR-HPV)阳性且子宫颈细胞学≥ASC-H的患者子宫颈上皮内瘤变(CIN)2+风险为72.2%(95%CI:62.8%~80.4%),高于既往进行过子宫颈癌筛查的59.6%(95%CI:45.8%~72.4%);CIN3+的风险为47.2%(95%CI:37.5%~57.1%),高于既往进行过子宫颈癌筛查的31.6%(95%CI:19.9%~45.2%)。子宫颈细胞学筛查结果≥ASC-H患者的CIN2+风险为58.3%(95%CI:43.2%~72.4%),高于既往进行过子宫颈癌筛查的45.5%(95%CI:24.4%~67.8%);CIN3+的风险为47.9%(95%CI:33.3%~62.8%),高于既往进行过筛查的19.0%(95%CI:5.4%~41.9%)。结论 定期进行子宫颈癌筛查可以降低子宫颈癌前病变/子宫颈癌的风险,提示阴道镜医生进行检查前,应进一步询问患者既往子宫颈癌筛查情况,结合本次筛查和阴道镜检查结果,能够更好地帮助医生判断子宫颈癌前病变/子宫颈癌的检出风险。

【Abstract】 Objective To investigate the role of cervical cancer screening history in assessing the risk of cervical precancerous lesions/cervical cancer, and to provide evidence for personalized management of cervical lesions. Methods A total of 2 832 non-pregnant women who underwent colposcopy from September to December in 2021 from 6 hospitals were retrospective analysis. Results The risk of CIN2 + of women without cervical cancer screening history in recent 5 years was 72.2%(95% CI: 62.8% ~ 80.4%) with HPV positive and cytology ≥ ASC-H, higher than 59.6%(95% CI: 45.8% ~ 72.4%) of those with cervical cancer screening history; the risk of CIN3 + also reached 47.2%(95% CI: 37.5% ~ 57.1%), higher than 31.6%(95% CI: 19.9% ~ 45.2%) of those with cervical cancer screening history in recent 5 years. The risk of CIN2+ of women without cervical cancer screening history was 58.3%(95% CI: 43.2% ~ 72.4%) with cytology ≥ ASC-H, higher than 45.5%(95% CI:24.4% ~ 67.8%) for those with cervical cancer screening history in recent 5 years, and 47.9%(95% CI: 33.3% ~ 62.8%) for CIN3 +,higher than the 19.0%(95% CI: 5.4% ~ 41.9%) of women with screening history. Conclusions Regular cervical cancer screening can reduce the risk of cervical precancerous lesions/cervical cancer. It is suggested that the doctor should learn the patients about their previous cervical cancer screening history before colposcopy examination.

  • 【文献出处】 中国妇产科临床杂志 ,Chinese Journal of Clinical Obstetrics and Gynecology , 编辑部邮箱 ,2025年04期
  • 【分类号】R737.33
  • 【下载频次】39
节点文献中: 

本文链接的文献网络图示:

本文的引文网络